Almac’s Sciences Business Unit will manufacture the production of MGB Biopharma's lead gram positive antibacterial compound MGB-BP3. The compound is a DNA minor groove binder and is currently in preclinical development, with IND filing targeted for Q3 2012.

MGB Bio's chief executive officer, Dr. Miroslav Ravic, commented, “We were very quickly impressed with the approach taken by Almac and they have already shown an intuitive understanding of what it takes to support a small company like ours. We look forward to a continued successful relationship.”

Rick Dyer, vice president Operations at Almac, remarked, “Almac has a wealth of expertise in early phase clinical development and we are delighted to undertake this phase of work for MGB Biopharma and hope this is the first of many successful projects between our companies.”